Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sold out at 43.43
Back in here just now at 42.33
Exactly
Yes
No brainer from here.
This is a gigot this AM IMO.
I just bought back in.
Yes
Should double from here. Agreement with Takeda in the bag.
This is a no brainer IMO
AEZS
I have a full position now at 1.39
I sold at 4.61
Good luck to those still holding
I'm out at 6.05
Average in at 5.27
I just got tired of waiting on the run. Good luck to you
GILD
11:34 EDT - Gilead (GILD) could be the world's second-biggest pharmaceutical company by net income in 2015 if Sovaldi sales keep growing, says Credit Suisse. It projects GILD's earnings to reach $15.1B next year, trailing just Johnson & Johnson's (JNJ) $18B, which of course sells much more than drugs. In 2013, GILD ranked 13th at $3.1B, says Credit Suisse. Sovaldi has had a record-setting launch the best launch of a new drug and is poised to help this year's GILD revenue more than double and EPS to quadruple. (jonathan.rockoff@wsj.com; @jonathanrockoff)
I bought some GILD on this AM's dip. I've done well flipping it several times.
Typical market over-reaction this AM. Bought in again at $102.60
just bought some more at 102.68
I wasn't in the market for more shares with my entry at $69 but I just couldn't pass up this obvious market over-reaction.
great buying opportunity this AM. IMO
If it goes below 43, I will jump back in
I have adjusted down to $6.35
me too.
Good luck to us. I have a full position again.
I'm out pre-market at 43.90
Yes
The selling is hurting the lift but once it stops it should jump nicely
The countdown to PDUFA on Sept 11 begins.
IMO, we are way undervalued.
This should double from here with approval next week.
The countdown to PDUFA on Sept 11 begins.
IMO, we are way undervalued.
This should double from here with approval next week.
Thanks
I've done well trading this one over the past couple of months.
OREX
Just bought another big block at 5.77
I just bought another big block at 5.77
Seems like a good morning to load some shares.
Market is down and artificially pulling this down this AM
Just bought more pre-market at 42.55
I agree
I think very good news is close
Yes
I just bought more
I'm back in here again for the third time.
Should climb into Nov 5 PDUFA
Looking very good with good accumulation taking place above $6
Getting ready for next leg up IMO
OREX
Very nice move the past two days ahead of PDUFA Sept 11
Broke $6 and staying above. Setting new floor at $6.05 range
Getting ready for next leg up.
IMO
Me too. Locked in some serious profits.
This was a very good play for me all around. Flipped it three times but this last one was king.
Good luck to all here!
Run is starting!!
OREX is starting to run.
Yes
Just had to take profits.
I bought more OREX with proceeds.
Just sold CPRX for a nice gain.
Good luck to all still long
Orexigen said that regulators and company officials needed more time to negotiate Orexigen’s post-marketing obligations for a continuing assessment of the drug’s potential cardiovascular risk—based on data from an ongoing trial of 8,900 patients known as the Light Study. The new deadline for action under the Prescription Drug User Fee Act (PDUFA) is September 11.
The issue of Orexigen’s post-marketing obligations arose late in the FDA review process, Orexigen senior vice president Preston Klassen, told analysts during a conference call. “Finalizing this post-marketing obligation for excluding cardiovascular risk is now the [only] issue we’re focusing on to complete the review,” Klassen said on the call.
“This is not an issue we have with the data,” added Orexigen CEO Michael Narachi. “This is not something about a signal in the data. It’s about closing on this post-marketing obligation.”
Do you mean this:
"The interim analysis of the Light Study clearly achieved the goal set by the FDA," said Michael Narachi, CEO of Orexigen. "The resubmission will contain an unprecedented amount of cardiovascular outcomes data for an obesity therapeutic, and we are confident these data will support a favorable benefit:risk assessment for Contrave."
The FDA previously agreed that if the interim analysis meets the specified criteria to exclude cardiovascular risk, Contrave could be approved. The pre-specified criteria for the interim analysis is to exclude a hazard ratio of 2.0, using the upper bound of the 95% confidence interval, for excess risk of major adverse cardiovascular events (MACE) in patients receiving Contrave as compared to placebo. In addition to meeting the pre-specified criteria for excluding cardiovascular risk, no new safety signals were observed.
OREX
Only 13 more trading days until PDUFA date.
This should heat up quickly IMO.
Seems very much undervalued at current price point which should make for a very quick, spring-loaded, climb.
JMHO
I think we need to start thinking about this as an investment and not a trade.
This is going to take at least 8 Q's to pan out. IMO
AEZS IMO
Only 21 days left until PDUFA date.
this should get very exciting very soon!
OREX
only 21 days left until PDUFA date.
This should get very exciting real soon.